Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. (PIRS) on June 28, 2024. The filing primarily addresses the termination of a material definitive agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, "Servier") regarding the development of the immuno-oncology asset S095012.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. However, it outlines potential future milestone and royalty payments from remaining partnerships with Boston Pharmaceuticals and Pfizer (formerly Seagen):
- Phase 2 Milestones: Up to $15 million aggregate upon first patient dosed for SGN-BB228 and BOS-342.
- Pivotal Trial Milestones: Up to $40 million aggregate upon first patient dosed for SGN-BB228 and BOS-342.
- Total Development Milestones: Up to $200 million for single, primary indications.
- Commercial Milestones: More than $415 million if approved.
- Additional Indications: Up to $130 million in additional developmental and commercial milestones.
Material Changes
Termination of Servier Collaboration: Servier provided written notice on June 28, 2024, to terminate the License and Collaboration Agreement and the Non-Exclusive Anticalin Platform Technology License Agreement. The termination is effective December 27, 2024 (180 days from notice).
Cessation of S095012 Development: Servier will discontinue and cease dosing in the Phase 1 clinical study of S095012 (a 4-1BB/PD-L1 bispecific Mabcalin protein) due to a potential safety concern. Pieris intends to review the safety data but does not intend to pursue further development of S095012.
Outlook, Risks, and Management Commentary
Strategic Focus: The Company is pursuing a strategy to maximize potential milestones from its remaining partnered 4-1BB bispecific Mabcalin assets while considering strategic opportunities to increase stockholder value.
Risks and Contingencies:
- Cash Runway: The Company notes that its cash runway may be reduced by unanticipated liabilities or decisions to pursue strategic opportunities.
- Listing Standards: There is a possibility the Company may face challenges in continuing to comply with Nasdaq listing standards, specifically those relating to operating company status.
- Partner Dependency: Future revenue is contingent on partners (Boston Pharmaceuticals and Pfizer) prioritizing, developing, and commercializing the assets, as well as achieving expected market share.
- Geopolitical and Market Risks: Risks include delays due to geopolitical conflicts (Ukraine, Middle East) and overall market conditions.
Investor Verification Checklist
- Verify the specific nature of the "potential safety concern" cited by Servier for terminating the S095012 program.
- Confirm the Company's current cash position and runway, as the filing highlights potential reductions due to liabilities.
- Review the status of Nasdaq compliance regarding operating company status.
- Monitor progress of SGN-BB228 and BOS-342 in Phase 1 trials to assess the likelihood of achieving the $15 million Phase 2 milestones.
- Assess the likelihood of partners (Boston Pharmaceuticals and Pfizer) continuing to prioritize these assets given the recent termination of the Servier deal.